Company intelligence / Profile preview

Antares Therapeutics

Boston, Massachusetts, United Statesantaresrx.com ↗

Ownership: Private
Development stage: Other

Overview

Antares Therapeutics, a Scorpion Therapeutics spin-out, is developing a pipeline of small molecule precision medicines targeting previously undruggable proteins in cancer and other serious diseases; its lead candidate is expected to enter clinical trials in 2026. The company retains rights to milestone payments and royalties from two clinical-stage EGFR inhibitors for non-small cell lung cancer, now developed by Pierre Fabre[1][2][3][4][5].

Therapeutic areas: OncologyOther
Modalities: Small molecule
Industry: Biotech

Drug pipeline

1 asset

ATX-898

Partnerships

AstraZeneca (collaboration on targeting transcription factors)Pierre Fabre Laboratories (EGFR inhibitors, out-licensed)

Beyond the preview

Go deeper on Antares Therapeutics.

Explore clinical development, deal activity, and the competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from trial design and recruitment through results.

Trial phase
Status
Readouts

Licensing & deals

Explore licensing agreements, acquisitions, and the assets behind each deal.

Partners
Deal terms
Milestones

Funding history

Trace financing activity and the investors behind a company’s development.

Funding rounds
Investors
Capital raised

Competitive landscape

Compare peer pipelines by target, modality, and therapeutic area.

Peer companies
Targets
Pipeline overlap

Technologies & patents

Explore technology platforms and the patent landscape around relevant assets.

Platforms
Patents
Assignees

Research & analysis

Connect company news and source material to the questions you’re investigating.

Company news
Sources
Analysis

Bring the full picture into focus.

See how Gosset can support your research on Antares Therapeutics.

Explore the full profile